The paronychia treatment market refers to the industry focused on developing and providing various products and therapies for the treatment of paronychia. Paronychia is a common infection that affects the skin surrounding the nails, causing pain, inflammation, and swelling. The market encompasses pharmaceuticals, topical creams and ointments, oral medications, and medical devices used for the diagnosis and treatment of paronychia.
In recent years, there has been a growing demand for effective and innovative treatments for paronychia, driving the expansion of the paronychia treatment market. Factors such as the increasing prevalence of nail infections, rising awareness about proper nail hygiene, and advancements in medical technology have contributed to the market’s growth.
The market offers a range of treatment options, including antifungal medications, antibiotics, corticosteroids, and surgical interventions in severe cases. Additionally, there has been a surge in the development of novel therapies, such as laser treatments and photodynamic therapy, aimed at providing more efficient and targeted solutions for paronychia.
Get Free Sample Copy of This Report – https://www.factmr.com/connectus/sample?flag=S&rep_id=8469
Key Takeaways from Market Study
- The global paronychia treatment market amounted to US$ 500 million in 2023.
- Worldwide demand for paronychia treatment is estimated to swell at a CAGR of 7.1% during the forecast period (2023 to 2033).
- The paronychia treatment market is set to reach US$ 1 billion by 2033.
- North America is ruling the global paronychia treatment market.
Key Segments of Paronychia Treatment Industry Research
-
By Type :
- Acute Paronychia
- Chronic Paronychia
-
By Product :
- Mupirocin Ointment
- Fusidic Acid Ointment
- Gentamicin Ointment
- Dicloxacillin
-
By End User :
- Hospitals & Clinics
- Dermatology Centers
-
By Region :
- North America
- Latin America
- Europe
- Asia Pacific & China
- Middle East & Africa
Competitive Landscape
Key players in the paronychia treatment market are constantly focusing on developing new items to gain a global market share. As a result, these players are increasing their investment in research and development to lead the worldwide market.
Many market players are focused more on collaboration and acquisition to expand their product portfolios, allowing them to boost their presence in the worldwide market and gain the most share. Furthermore, market players are constantly attempting to close the gap between the demand and supply of quality therapy to boost profit. Start-ups operating in the global market are also concentrating on developing innovative products.
- The US Food and Drug Administration approved Bausch Health’s Jublia in April 2021. Jublia is a topical solution used to treat paronychia in patients aged six and up.
- Mundipharma struck a new agreement in November 2020 with Moberg Pharma to market its consumer healthcare product for treating nail disorders throughout the Middle East & Africa (MEA). The company specializes in topical therapy for nail and skin disorders.
Key Companies Profiled in Paronychia Treatment Market report
- Glenmark Generics Ltd
- GlaxoSmithKline plc
- Eli Lilly Company
- Teva Pharmaceutical Industries Ltd
- Fougera Pharmaceuticals Inc
- Jonakayem Pharma Formulation
More Valuable Insights on Offer
Fact.MR, in its new offering, presents an unbiased analysis of the global paronychia treatment market, presenting historical demand data (2018 to 2022) and forecast statistics for the period (2023 to 2033).
The study divulges essential insights on the market based on type (acute paronychia, chronic paronychia), product (mupirocin ointment, fusidic acid ointment, gentamicin ointment, dicloxacillin), and end user (hospitals & clinics, dermatology centers), across five major regions of the world (North America, Europe, Asia Pacific, Latin America, and MEA).
Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583